HQ Capital is an independent alternative investment manager based in Bad Homburg, Germany, with over $12 billion in assets under management across private equity and real estate. Established in 2015 through the merger of Auda, Real Estate Capital Partners, and Equita, the firm has a rich history dating back to 1989. HQ Capital focuses on identifying and investing alongside private equity managers in North America, Europe, and Asia, particularly in the lower-middle market buyouts sector. With professional teams operating globally, the company leverages its extensive network and local market expertise to tailor investment solutions that align with client needs. HQ Capital is dedicated to generating long-term attractive returns while ensuring that its investment decisions prioritize the interests of clients. The firm’s business model fosters alignment between its interests and those of its clients, supported by significant financial commitments from its senior team and the Harald Quandt family, a notable anchor investor.
14/F Henley Building 5 Queen’s Road; Central, Hong Kong, China
Amit Dabas
Director
Michael Hu
Managing Director and Executive Committee Member
Patrick Knoefler
Managing Director and Executive Committee Member
Britta Lindhorst
Managing Director, Head of European Investments and Global Head of ESG / Impact
Oliver Schlümer
Director
Kenneth Ward-Smith
Managing Director
Stephen Wesson
Managing Director, General Partner, Executive Committee Member and Investment Committee Member
Benjamin Wilson
Managing Director, Global Head of Secondaries
Lily Young
Associate
1 past transactions
Interlace Medical
Series C in 2009
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.